跳至主要内容
临床试验/NCT00002031
NCT00002031已完成不适用

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

University of California, San Francisco1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
试验地点
1

研究概览

简要总结

To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients must have the following:
  • •Stage III or IV HIV infection.
  • •Provide informed consent.

排除标准

  • •Co-existing Condition:
  • •Patients with the following conditions or symptoms are excluded:
  • •Kaposi's sarcoma lesions in the proposed treatment sites.
  • •Liable to require radiation or chemotherapy during the course of the study.
  • •Not likely to survive the length of the study.
  • •Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:
  • •holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.
  • •Concurrent Medication:
  • •Other Immunomodulators.
  • •Concurrent Treatment:
  • •Radiation.
  • •Patients with the following are excluded:
  • •Kaposi's sarcoma lesions in the proposed treatment sites.
  • •Liable to require radiation or chemotherapy during the course of the study.
  • •Not likely to survive the length of the study.
  • •Obvious ultra-violet-irradiated skin damage in the treatment areas.
  • •Allergy to lidocaine.
  • •Prior Medication:
  • •Prior DNCB therapy.

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验